2024
Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project
Javanbakht A, Stringer S, Anderson H, Hamilton E, Philip A, Waller E, Langston A, Joseph N, Roback J, Schneider T, Sullivan H, Hendrickson J. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G‐CSF and Plerixafor: A single center project. Journal Of Clinical Apheresis 2024, 39: e22127. PMID: 38803152, DOI: 10.1002/jca.22127.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzylaminesBlood Component RemovalCyclamsFemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansMaleMiddle AgedMultiple MyelomaPeripheral Blood Stem Cell TransplantationPlatelet CountRetrospective StudiesTransplantation, AutologousConceptsStem cell collectionPlatelet countG-CSFMultiple myelomaAutologous peripheral blood stem cell collectionApheresis collectionsPeripheral blood stem cell collectionAutologous stem cell collectionBlood stem cell collectionCell collectionPre-emptive plerixaforBaseline platelet countTransplant doseAutologous collectionApheresisPatientsMedical recordsPlerixaforCollection goalDay of collectionQuality improvement initiativesMyelomaPoor mobilityPlateletCount
2022
The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan
Josephson CD, Glynn S, Mathew S, Birch R, Bakkour S, Kreuziger L, Busch MP, Chapman K, Dinardo C, Hendrickson J, Hod EA, Kelly S, Luban N, Mast A, Norris P, Custer B, Sabino E, Sachais B, Spencer BR, Stone M, Kleinman S, for the National Heart L. The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion 2022, 62: 982-999. PMID: 35441384, PMCID: PMC9353062, DOI: 10.1111/trf.16869.Peer-Reviewed Original ResearchConceptsBlood safety issueRecipient outcomesData Coordinating CenterRecipient EpidemiologySevere acute respiratory syndrome corona virus 2Blood donor safetyNon-transfused patientsProspective observational studyHospital electronic medical recordsCorona virus 2Sickle cell diseaseElectronic medical recordsPreterm infantsDonor safetyNational HeartMedical recordsBlood donorsCell diseaseObservational studyBlood supplyTransfusion outcomesBlood centersStudy designSpecial populationsCoordinating Center
2019
Chapter 56 Management of Patients Who Refuse Blood Transfusion
Bahar B, Hendrickson J. Chapter 56 Management of Patients Who Refuse Blood Transfusion. 2019, 357-360. DOI: 10.1016/b978-0-12-813726-0.00056-8.Peer-Reviewed Original ResearchBlood productsRed blood cellsBlood transfusionBlood management programManagement of patientsJehovah's Witness faithCertain blood componentsBlood lossCoagulation defectsMedical recordsPatientsAnemia toleranceTransfusionBlood componentsBlood cellsRBC productionExcellent communicationManagement programCliniciansHemostasisGranulocytes
2009
Chapter 48 Management of Patients Who Refuse Blood Transfusion
Hendrickson J, Roback J. Chapter 48 Management of Patients Who Refuse Blood Transfusion. 2009, 279-282. DOI: 10.1016/b978-0-12-374432-6.00048-8.Peer-Reviewed Original ResearchBlood transfusionDocumentation of refusalMinority of patientsManagement of patientsIntraoperative blood salvageMedical therapyPlasma exchangePregnant womenBlood managementBlood salvageMedical recordsTransfusionMedical treatmentPatientsBlood donationStandard transfusionsJehovah's WitnessesHuman bloodTreatmentCompetent adultsUnacceptable treatmentHemodilutionTherapyRelated proceduresManagement